Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study-Reference-Cited by-同舟云学术

Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study

Published:2018-08-13 Issue:6 Volume:11 Page:470-482
ISSN:1937-5387
Container-title:Journal of Cardiovascular Translational Research
language:en
Short-container-title:J. of Cardiovasc. Trans. Res.

Author:

Lintas V.,Fioretta E. S.,Motta S. E.,Dijkman P. E.,Pensalfini M.,Mazza E.,Caliskan E.,Rodriguez H.,Lipiski M.,Sauer M.,Cesarovic N.,Hoerstrup S. P.,Emmert M. Y.

Funder

Schweizerische Herzstiftung

Forschungskredit Candoc program of the University of Zurich

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine

Link

http://link.springer.com/article/10.1007/s12265-018-9821-1/fulltext.html

Reference39 articles.

1. Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin 3rd, J. P., Guyton, R. A., et al. (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. The Journal of Thoracic and Cardiovascular Surgery, 148(1), e1–e132.

2. Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., et al. (2015). 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 385(9986), 2485–2491.